Last reviewed · How we verify
NCT05090098
Breast Cancer and Kinesiophobia and Physical Activity
trial testing None intervention in Breast Cancer in 180 participants. Completed in 15 May 2022.
15 November 2021
Quick facts
| Lead sponsor | Acibadem University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 1 August 2021 |
| Primary completion | 15 November 2021 |
| Estimated completion | 15 May 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- None intervention
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Kinesiophobia — all drugs for Kinesiophobia →
Sponsor
Acibadem University
Who can join
Adults 18 to 75, female only, with Breast Cancer or Kinesiophobia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast cancer is the most common type of cancer in women worldwide. A significant number of breast cancer survivors develop many complications. Breast cancer and survivors may develop a fear of physical activity avoidance and movement, called kinesiophobia, due to upper extremity pain, numbness, restricted arm/shoulder range of motion, and risk of lymphedema. Therefore, in the present study, it is aimed to compare the effect of fear of movement on physical activity, quality of life and psychological states in women who have had breast cancer with healthy people.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05090098
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of None intervention
Trials testing the same drug.
- NCT07198152 — Artificial Intelligence Used in Screening Adrenal Nodules · recruiting
- NCT07166445 — Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT · recruiting
- NCT06193447 — Early Mobilization in Cardiac Surgery · completed
- NCT05302869 — Perceptions of Physiotherapy and Rehabilitation Professions · completed
- NCT05014750 — Frailty of Elderly With Valvular Heart Disease and the Short Term Adverse Events · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Acibadem University trials
Trials by the same sponsor.
- NCT07481864 — The Effect of Early-Phase Graded Motor Imagery Following Massive Rotator Cuff Repair. · NA · not yet recruiting
- NCT07488377 — Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease · not yet recruiting
- NCT07488364 — Determinants of Physical Frailty in Parkinson's Disease: A Multi-Factorial Analysis · not yet recruiting
- NCT07488351 — "Self-Compassion and Self-Efficacy in Parkinson's Disease: Associations With Symptoms, Function, and Quality of Life" · not yet recruiting
- NCT07413185 — Relationship Between the Severity of Sleep Deprivation in the First 48 Hours Postpartum, Breastfeeding Motivation, and B · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05090098 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Acibadem University
- Last refreshed: 1 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05090098.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing